Pulido Tomas, de la Cruz-Perez Sofia, Valencia Daniela, Conde Rafael, Lescano Adrian, Zayas Nayeli
From the Clinical Research Department, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico.
From the Systematic Support Office for Higher Research (OASIS), Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico.
Int J Cardiol Congenit Heart Dis. 2025 Jan 31;19:100573. doi: 10.1016/j.ijcchd.2025.100573. eCollection 2025 Mar.
Pulmonary arterial hypertension (PAH) has been classically described as a disease in young adults, predominantly females with no comorbidities. However, in recent registries, the epidemiology has changed to older patients with comorbidities such as obesity, diabetes, systemic hypertension, and coronary heart disease. Nevertheless, there is not enough inclusion of these patients in clinical trials. In contrast, in Latin America, registries have shown that PAH patients are younger and have fewer comorbidities, which raises the question of whether Latin American patients present a different phenotype or if we are lagging behind developed countries and whether we will experience a change in epidemiology in the next couple of years. We analyzed these trends in this review.
肺动脉高压(PAH)传统上被描述为一种好发于年轻成年人的疾病,主要是无合并症的女性。然而,在最近的登记研究中,流行病学情况已转变为更多的是患有肥胖、糖尿病、系统性高血压和冠心病等合并症的老年患者。尽管如此,临床试验中对这些患者的纳入仍不足。相比之下,在拉丁美洲,登记研究表明PAH患者更年轻且合并症较少,这就引发了一个问题,即拉丁美洲患者是否呈现出不同的表型,或者我们是否落后于发达国家,以及在未来几年我们是否会经历流行病学的变化。我们在这篇综述中分析了这些趋势。